Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.
The company’s clinical-stage product candidates include:
- ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
- Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
- Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
- Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.
Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.
Recent news highlights Kiniksa’s progress:
- In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
- In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
- In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.
For more information about Kiniksa and its pipeline, visit www.kiniksa.com.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:35 a.m. Eastern Time.
The presentation will be accessible via live webcast through the Investors section of Kiniksa's website at www.kiniksa.com. A replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 2024 Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT (7:00 a.m. ET).
Interested parties can access a live webcast of the presentation through the Investors section of Kiniksa's website at www.kiniksa.com. A replay will be made available on the company's website within 48 hours after the event.
Kiniksa Pharmaceuticals reported strong Q3 2024 financial results, with ARCALYST generating net product revenue of $112.2 million, representing 73% year-over-year growth. The company raised its 2024 ARCALYST revenue guidance to $410-420 million. Since its April 2021 launch, over 2,550 prescribers have written ARCALYST prescriptions for recurrent pericarditis, with average therapy duration reaching 27 months. The company reported a Q3 net loss of $12.7 million but maintains $223.8 million in cash and investments with no debt. Kiniksa expects to remain cash flow positive annually while advancing its pipeline, including the Phase 2b trial of abiprubart in Sjögren's Disease.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with GRAMMY Award-winning singer-songwriter Carly Pearce to expand its Life DisRPted™ campaign, focusing on raising awareness for recurrent pericarditis. The campaign aims to promote early diagnosis and treatment of this rare, chronic autoinflammatory disease. Pearce, who was diagnosed with recurrent pericarditis while on tour in May 2024, joins the initiative to support patients and caregivers affected by the condition.
The campaign serves as a platform to encourage both patients and healthcare providers to recognize signs of recurrent pericarditis and develop appropriate treatment plans to minimize its impact on patients' lives. More information about the campaign and the condition can be found at LifeDisRPted.com.
Kiniksa Pharmaceuticals International (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, October 29, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. The live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com.
Individuals interested in participating via telephone can register online to receive dial-in information. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with NHL Hall-of-Famer Henrik Lundqvist to launch the Life DisRPted campaign, focusing on raising awareness of recurrent pericarditis. This national initiative aims to promote early diagnosis and treatment of this painful, debilitating chronic autoinflammatory disease.
Lundqvist, diagnosed with recurrent pericarditis in 2021, shares his personal journey in a video titled 'Comeback After Comeback'. The campaign website, LifeDisRPted.com, features this video along with a downloadable Doctor Discussion Guide to help patients communicate with healthcare providers.
Dr. Antonio Abbate, Professor of Cardiology at The University of Virginia, emphasizes the importance of early diagnosis and proactive collaboration with healthcare providers in managing recurrent pericarditis. The campaign seeks to support patients, reduce feelings of isolation, and encourage self-advocacy in disease management.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 4, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access a live webcast of Kiniksa's presentation through the Investors & Media section of the company's official website at www.kiniksa.com. For those unable to attend the live event, a replay will be made available on Kiniksa's website within approximately 48 hours after the presentation concludes.
Kiniksa Pharmaceuticals reported strong Q2 2024 financial results, with ARCALYST net product revenue of $103.4 million, representing 90% year-over-year growth. The company increased its 2024 ARCALYST revenue guidance to $405-$415 million. Key highlights include:
1. Approximately 11% of the 14,000 multiple-recurrence target population actively on ARCALYST treatment.
2. Average total duration of ARCALYST therapy increased to ~26 months.
3. Enrollment began in the abiprubart Phase 2b trial for Sjögren's Disease.
4. Total revenue for Q2 2024 was $108.6 million.
5. Net loss for Q2 2024 was $3.9 million.
6. Cash position of $218.8 million with no debt as of June 30, 2024.
Kiniksa expects to remain cash flow positive on an annual basis, with abiprubart's clinical development fully funded in the current operating plan.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals has begun enrolling patients in a Phase 2b clinical trial for abiprubart, a humanized anti-CD40 monoclonal antibody, aimed at treating Sjögren’s Disease, a debilitating autoimmune disorder. The trial will assess the efficacy of abiprubart administered biweekly and monthly via subcutaneous injections over a 24-week period, involving around 201 participants. The primary measure of success is the change in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to a placebo. The study will also include a long-term extension phase where all participants receive active treatment. Importantly, Kiniksa expects to remain cash flow positive during this development.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is Kiniksa Pharmaceuticals' primary focus?
What are the key products in Kiniksa's pipeline?
What recent achievements has Kiniksa Pharmaceuticals reported?
What is ARCALYST used for?
When was Kiniksa's latest financial report released?
What is the expected revenue for ARCALYST in 2024?
What is abiprubart (KPL-404) targeting?
What are some of the conditions Kiniksa is targeting with its therapies?
Where can I find more information about Kiniksa Pharmaceuticals?
Who should be contacted for investor and media inquiries?
